Hussein Tawbi, MD, PhD, details the incidence rate of melanoma and that appropriate diagnosis includes an MRI to check for brain metastases and molecular testing for BRAF mutations.
Dosing and Regimen Changes Promote Tolerability in Advanced Melanoma
March 14th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Michael B. Atkins, MD, discussed dosing considerations and toxicity when choosing combination treatment for patients with melanoma. This is the second of 2 articles based on this event.
Read More